{"id":"ferric-iii-carboxymaltose","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypophosphatemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The carboxymaltose ligand stabilizes ferric iron in a form that can be safely administered intravenously, allowing rapid iron delivery without the gastrointestinal side effects of oral iron. The iron is taken up by transferrin and incorporated into hemoglobin and iron-storage proteins to restore oxygen-carrying capacity and correct anemia.","oneSentence":"Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:48.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in adults"},{"name":"Iron deficiency anemia in patients with chronic kidney disease"},{"name":"Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron"}]},"trialDetails":[{"nctId":"NCT06437080","phase":"NA","title":"Hypoferritinemia Without Anemia Among Reproductive Age Females","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akram Medical Complex","startDate":"2022-10-10","conditions":"Hypoferritenemia Without Anemia (HWA), Iron Deficiency Without Anemia)","enrollment":1331},{"nctId":"NCT03231085","phase":"NA","title":"Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-10-31","conditions":"Craniosynostosis","enrollment":100},{"nctId":"NCT05744219","phase":"PHASE3","title":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","status":"RECRUITING","sponsor":"Jon Unosson","startDate":"2024-09-04","conditions":"Surgery, Liver Metastases, Liver Cancer","enrollment":338},{"nctId":"NCT03769441","phase":"PHASE3","title":"Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-08-02","conditions":"Iron-deficiency, Transplant-Related Disorder","enrollment":148},{"nctId":"NCT02694978","phase":"PHASE3","title":"A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)","status":"COMPLETED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2016-02-29","conditions":"Iron Deficiency Anemia","enrollment":2014},{"nctId":"NCT00520780","phase":"PHASE3","title":"Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2007-04","conditions":"Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia","enrollment":456},{"nctId":"NCT04475887","phase":"PHASE4","title":"Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-07-23","conditions":"Liver Transplantation, Blood Loss","enrollment":60},{"nctId":"NCT01692418","phase":"PHASE3","title":"Preoperative Intravenous Iron to Treat Anaemia in Major Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2014-01","conditions":"Anaemia","enrollment":487},{"nctId":"NCT02271997","phase":"PHASE4","title":"Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2014-12-04","conditions":"Iron Deficiency","enrollment":120},{"nctId":"NCT02243735","phase":"PHASE4","title":"Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-11","conditions":"Anemia, Colorectal Carcinoma, Surgery","enrollment":198},{"nctId":"NCT02125344","phase":"PHASE3","title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2014-12","conditions":"Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II","enrollment":961},{"nctId":"NCT02210949","phase":"PHASE4","title":"Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery","status":"TERMINATED","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2014-08","conditions":"Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency","enrollment":7},{"nctId":"NCT01725789","phase":"PHASE3","title":"Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2012-11","conditions":"Anemia","enrollment":454},{"nctId":"NCT00821717","phase":"PHASE3","title":"EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure","status":"TERMINATED","sponsor":"Vifor Pharma","startDate":"2008-12","conditions":"Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ferinject"],"phase":"marketed","status":"active","brandName":"ferric(III)carboxymaltose","genericName":"ferric(III)carboxymaltose","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia. Used for Iron deficiency anemia in adults, Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}